Alectinib hydrochloride (Alecensa) is an oral capsule formulated at a 150 mg dosage for medical use [1].
What is Alecensa used for?
Alecensa is a medication prescribed for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) [1]. It is particularly indicated for individuals whose disease has progressed on or after treatment with crizotinib or when crizotinib is not considered appropriate [1].
How does Alecensa work?
Alectinib is a tyrosine kinase inhibitor (TKI) that specifically targets ALK [1]. ALK rearrangements in NSCLC lead to abnormal signaling that drives cancer cell growth and survival. By inhibiting ALK, alectinib blocks this signaling pathway, thereby suppressing tumor growth [1].
When does Alecensa's patent protection expire?
Patent information for Alecensa can be found on DrugPatentWatch.com. For specific details regarding patent expiry dates, it is advisable to consult specialized patent databases [2].
What are the common side effects of Alecensa?
Common side effects reported by patients taking Alecensa include fatigue, constipation, swelling in the hands or feet, muscle pain, nausea, and shortness of breath [1].
Are there any contraindications or warnings for Alecensa?
Patients with a known hypersensitivity to alectinib or any of its components should not take Alecensa [1]. It is important to discuss any pre-existing medical conditions, especially liver problems or slow heart rate, with a healthcare provider before starting treatment [1].
Can other drugs be taken with Alecensa?
The use of certain medications can affect how Alecensa works or increase the risk of side effects. For instance, strong CYP3A inhibitors may increase alectinib exposure, while strong CYP3A inducers may decrease it [1]. Always inform your doctor about all medications, including over-the-counter drugs and herbal supplements, you are taking [1].
What clinical trials support Alecensa's efficacy?
The efficacy of Alecensa was established in a global, randomized, open-label study where patients with previously treated ALK-positive metastatic NSCLC received either alectinib or chemotherapy [1].
Sources:
1. https://www.alecensa.com/
2. https://www.drugpatentwatch.com/